Impact of ABO Blood Type on Outcomes in Patients with Primary Nonmuscle Invasive Bladder Cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F14%3A10292794" target="_blank" >RIV/00064203:_____/14:10292794 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/14:10292794

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.juro.2013.11.106" target="_blank" >http://dx.doi.org/10.1016/j.juro.2013.11.106</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.juro.2013.11.106" target="_blank" >10.1016/j.juro.2013.11.106</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Impact of ABO Blood Type on Outcomes in Patients with Primary Nonmuscle Invasive Bladder Cancer

Popis výsledku v původním jazyce

Purpose: ABO blood type is an established prognostic factor for several malignancies but its role in bladder urothelial carcinoma is largely unknown. We determined whether ABO blood type is associated with the outcome of transurethral resection of nonmuscle invasive bladder urothelial carcinoma. Materials and Methods: We retrospectively studied ABO blood types in 931 patients with primary nonmuscle invasive bladder urothelial carcinoma treated with transurethral bladder resection with or without intravesical instillation therapy. Disease recurrence and progression were analyzed with univariable and multivariable competing risks regression models. Median followup was 67 months. Discrimination was evaluated by the concordance index. Results: The ABO blood type was O, A, B and AB in 414 (44.5%), 360 (38.7%), 103 (11.1%) and 54 patients (5.8%), respectively. ABO blood type was significantly associated with outcome on univariable and multivariable analysis. Overall, patients with blood type

Název v anglickém jazyce

Impact of ABO Blood Type on Outcomes in Patients with Primary Nonmuscle Invasive Bladder Cancer

Popis výsledku anglicky

Purpose: ABO blood type is an established prognostic factor for several malignancies but its role in bladder urothelial carcinoma is largely unknown. We determined whether ABO blood type is associated with the outcome of transurethral resection of nonmuscle invasive bladder urothelial carcinoma. Materials and Methods: We retrospectively studied ABO blood types in 931 patients with primary nonmuscle invasive bladder urothelial carcinoma treated with transurethral bladder resection with or without intravesical instillation therapy. Disease recurrence and progression were analyzed with univariable and multivariable competing risks regression models. Median followup was 67 months. Discrimination was evaluated by the concordance index. Results: The ABO blood type was O, A, B and AB in 414 (44.5%), 360 (38.7%), 103 (11.1%) and 54 patients (5.8%), respectively. ABO blood type was significantly associated with outcome on univariable and multivariable analysis. Overall, patients with blood type

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Urology

ISSN

0022-5347

e-ISSN

—

Svazek periodika

191

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

6

Strana od-do

1238-1243

Kód UT WoS článku

000335147100009

EID výsledku v databázi Scopus

—